A double-blind,
placebo-controlled trial of memantine in age-associated memory
impairment (memantine in AAMI).
Ferris S, Schneider L, Farmer
M, Kay G, Crook T.
Alzheimer's Disease Center
Silberstein Institute,
New York University School of Medicine
New York, NY
Abstract
OBJECTIVES: To determine the safety and
efficacy of memantine in treating Age-Associated Memory Impairment
(AAMI).
METHODS: Sixty adults between 50-79 years of age meeting diagnostic
requirements for AAMI were randomly assigned to either memantine
(titrated to 20 mg) or a matched placebo and treated for 90 days. An
extensive battery of computerized cognitive tests was administered at
screening, baseline and, thereafter, at monthly intervals.
RESULTS AND CONCLUSION: Study results suggest that the primary cognitive
effects of memantine in this population are on attention and information
processing speed, rather than on memory. There were no differences in
adverse events between memantine and placebo.